11-JUN-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3649 262 108 63 21 1 02/06/2019 439 184
Screened at PD     1271 62 31 20 7 0      
Pre-Screened prior to PD     2372 194 71 37 12 0      
Treatment-naive     6 6 6 6 2 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     505 59 10 7 1 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     1903 184 150 148 15 6      
Screened at PD     1046 70 55 53 8 2      
Pre-Screened prior to PD     796 105 86 86 5 2      
Treatment-naive     6 6 6 6 2 2      
After PD on a Lung_MAP Sub-Study     55 3 3 3 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     134 134 134 134 11 2      
S1900G     30 11 3 2 0 0      
S1900J     12 12 4 3 1 1      
S1900K     17 15 9 9 3 3      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     506 25 13 11 3 0      
Initial sub-study registrations     494 25 13 11 3 0      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 2 2 2 2 2 0 05/22/2025 241 68
Docetaxel plus Ramucirumab Y   1 1 1 1 1 0      
Cemiplimab plus Docetaxel and Ramucirumab Y   1 1 1 1 1 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 20 8 4 3 0 0 05/05/2023 283 104
Capmatinib + Osimertinib + Ramucirumab Y   10 5 3 2 0 0      
Capmatinib + Osimertinib Y   10 3 1 1 0 0      
S1900J: MET Amplification: Amivantamab-SC   88 2 2 1 1 0 0 11/19/2024 188 72
Amivantamab SC Y   2 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 8 8 6 5 1 0 08/08/2024 259 85
Tepotinib + Ramucirumab Y   6 6 5 4 1 0      
Tepotinib Y   2 2 1 1 0 0